Balance Sheet
Cash Flow Statement
AmortizationOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Net Cash Flow (2016 - 2022)

Historic Net Cash Flow for RedHill Biopharma (RDHL) over the last 11 years, with Q4 2022 value amounting to -$2.4 million.

  • RedHill Biopharma's Net Cash Flow fell 13898.55% to -$2.4 million in Q4 2022 from the same period last year, while for Dec 2023 it was -$2.4 million, marking a year-over-year increase of 7780.93%. This contributed to the annual value of -$961000.0 for FY2024, which is 9331.57% up from last year.
  • According to the latest figures from Q4 2022, RedHill Biopharma's Net Cash Flow is -$2.4 million, which was down 13898.55% from -$6.0 million recorded in Q3 2022.
  • RedHill Biopharma's Net Cash Flow's 5-year high stood at $52.5 million during Q1 2020, with a 5-year trough of -$59.4 million in Q2 2020.
  • Over the past 5 years, RedHill Biopharma's median Net Cash Flow value was -$1.2 million (recorded in 2022), while the average stood at $104250.0.
  • Its Net Cash Flow has fluctuated over the past 5 years, first surged by 97331.45% in 2020, then tumbled by 82101.54% in 2021.
  • Over the past 5 years, RedHill Biopharma's Net Cash Flow (Quarter) stood at $10.3 million in 2018, then skyrocketed by 67.7% to $17.3 million in 2019, then tumbled by 82.19% to $3.1 million in 2020, then soared by 101.1% to $6.2 million in 2021, then tumbled by 138.99% to -$2.4 million in 2022.
  • Its Net Cash Flow stands at -$2.4 million for Q4 2022, versus -$6.0 million for Q3 2022 and -$1.8 million for Q2 2022.